The FDA has expanded the approval of pirtobrutinib for the first-line treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who do not have a known 17p deletion. This approval is based on results from the randomized BRUIN-CLL-313 trial, which demonstrated a 80% reduction in the risk of disease progression or death compared to chemoimmunotherapy. Median progression-free survival was not estimable in the pirtobrutinib arm. The overall response rate reached 94% with pirtobrutinib versus 81% with bendamustine plus rituximab. Doctors can now consider pirtobrutinib for appropriate patients when initial therapy is needed. Pirtobrutinib was first approved for pretreated CLL/SLL and has shown activity in patients with Richter transformation and mantle cell lymphoma. The BRUIN-CLL-313 trial also demonstrated consistent safety and tolerability. Common non-laboratory adverse events included upper respiratory tract infections, rash, and COVID-19. Common grade 3/4 laboratory abnormalities included decreased neutrophil counts. Serious adverse events occurred in 28% of patients, with warnings and precautions including infections, hemorrhage, cytopenias, cardiac arrhythmias, secondary primary malignancies, hepatotoxicity, and embryo-fetal toxicity.